Accelerated resolution of inflammation underlies sex differences in inflammatory responses in humans

Krishnaraj S Rathod, Vikas Kapil, Shanti Velmurugan, Rayomand S Khambata, Umme Siddique, Saima Khan, Sven Van Eijl, Lorna C Gee, Jascharanpreet Bansal, Kavi Pitrola, Christopher Shaw, Fulvio D'Acquisto, Romain A Colas, Federica Marelli-Berg, Jesmond Dalli, Amrita Ahluwalia, Krishnaraj S Rathod, Vikas Kapil, Shanti Velmurugan, Rayomand S Khambata, Umme Siddique, Saima Khan, Sven Van Eijl, Lorna C Gee, Jascharanpreet Bansal, Kavi Pitrola, Christopher Shaw, Fulvio D'Acquisto, Romain A Colas, Federica Marelli-Berg, Jesmond Dalli, Amrita Ahluwalia

Abstract

Background: Cardiovascular disease occurs at lower incidence in premenopausal females compared with age-matched males. This variation may be linked to sex differences in inflammation. We prospectively investigated whether inflammation and components of the inflammatory response are altered in females compared with males.

Methods: We performed 2 clinical studies in healthy volunteers. In 12 men and 12 women, we assessed systemic inflammatory markers and vascular function using brachial artery flow-mediated dilation (FMD). In a further 8 volunteers of each sex, we assessed FMD response to glyceryl trinitrate (GTN) at baseline and at 8 hours and 32 hours after typhoid vaccine. In a separate study in 16 men and 16 women, we measured inflammatory exudate mediators and cellular recruitment in cantharidin-induced skin blisters at 24 and 72 hours.

Results: Typhoid vaccine induced mild systemic inflammation at 8 hours, reflected by increased white cell count in both sexes. Although neutrophil numbers at baseline and 8 hours were greater in females, the neutrophils were less activated. Systemic inflammation caused a decrease in FMD in males, but an increase in females, at 8 hours. In contrast, GTN response was not altered in either sex after vaccine. At 24 hours, cantharidin formed blisters of similar volume in both sexes; however, at 72 hours, blisters had only resolved in females. Monocyte and leukocyte counts were reduced, and the activation state of all major leukocytes was lower, in blisters of females. This was associated with enhanced levels of the resolving lipids, particularly D-resolvin.

Conclusions: Our findings suggest that female sex protects against systemic inflammation-induced endothelial dysfunction. This effect is likely due to accelerated resolution of inflammation compared with males, specifically via neutrophils, mediated by an elevation of the D-resolvin pathway.

Trial registration: ClinicalTrials.gov NCT01582321 and NRES: City Road and Hampstead Ethics Committee: 11/LO/2038.

Funding: The authors were funded by multiple sources, including the National Institute for Health Research, the British Heart Foundation, and the European Research Council.

Conflict of interest statement

A. Ahluwalia is a director of Heartbeet Ltd.

Figures

Figure 1. Flow charts of clinical studies.
Figure 1. Flow charts of clinical studies.
(A) Study 1. (B) Study 2. PWV, pulse wave velocity; PWA, pulse wave analysis; FMD, flow-mediated dilatation.
Figure 2. Low-grade systemic inflammation induced by…
Figure 2. Low-grade systemic inflammation induced by typhoid vaccination enhances neutrophil activation state in healthy male but not female volunteers.
Changes in expression of (A) CD11b, (B) CD162, and (C) CD62L on neutrophils in male and female healthy volunteers at baseline, 8 hours, and 32 hours following typhoid vaccine administration. Changes in expression of (D) CD11b, (E) CD162, and (F) CD62L from baseline in male and female healthy volunteers at 8 hours and 32 hours following typhoid vaccine administration. Data expressed as mean ± SEM of n = 12 male and female volunteers for all the panels. Statistical significance determined using 2-way ANOVA with Šídák’s post hoc analysis; *P < 0.05 for all panels.
Figure 3. Low-grade systemic inflammation induced by…
Figure 3. Low-grade systemic inflammation induced by typhoid vaccination does not cause endothelial dysfunction in healthy female volunteers.
The effect of typhoid vaccination on (A) FMD measured at baseline and 8 and 32 hours following typhoid vaccination. (B)The effect of sex on the change in FMD at 8 hours following typhoid vaccination from baseline All data are expressed as mean ± SEM of n = 12 for each sex. Statistical significance determined using (A) 2-way ANOVA with Šídák’s post hoc analysis, **P < 0.01; and (B) Student’s 2-tailed unpaired test. Maximal dilatation of the brachial artery in response glyceryl trinitrate in (C) male and (D) female healthy volunteers measured at baseline and 8 and 32 hours following typhoid vaccination. Data expressed as mean ± SEM of n = 8. Statistical significance determined using 1-way ANOVA with Šídák’s post-hoc analysis.
Figure 4. Reduced inflammatory response to cantharidin…
Figure 4. Reduced inflammatory response to cantharidin in female compared with male healthy volunteers.
The total (A) volume of fluid, (B) cell count, (C) neutrophil count, (D) inflammatory monocyte count, and (E) CD4+ and (F) CD8+ T cell count at 24 hours and 72 hours following application of cantharidin to the volar aspect of the forearm. Data is shown as mean ± SEM of n = 16 of each sex for all the panels. Statistical analysis was determined using 2-way ANOVA followed by Šídák’s post tests; #P < 0.05, ##P < 0.01 for all panels.
Figure 5. Reduced inflammatory cell activation state…
Figure 5. Reduced inflammatory cell activation state in cantharidin-induced blister exudates in female compared with male healthy volunteers.
Mean fluorescence intensity (MFI) of the expression molecules CD162, CD62L, and CD11b on (A) neutrophils, (B) inflammatory monocytes, and (C) CD4+ and CD8+ T cells in healthy male (n = 16) and female (n = 16) volunteers. Data are shown as mean ± SEM. Statistical significances determined using 2-way ANOVA, *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001; followed by Šídák’s post tests, #P < 0.05, ##P < 0.01, and ####P < 0.0001 comparing the sexes at each time point for all the panels.
Figure 6. Female blister exudates display a…
Figure 6. Female blister exudates display a pro-resolving mediator profile.
Lipid mediators from exudates were extracted using C18 solid-phase extraction and profiled using LC-MS/MS–based lipid mediator profiling. (A) Representative multiple reaction monitoring chromatograms for identified lipid mediators and pathway markers from the 3 major bioactive metabolomes (left panel) and MS/MS spectra employed for their identification (right panel). (B) Partial least squares discriminant analysis of exudate lipid mediator profiles: left panel, 2D score plot; right panel, corresponding 2D loading plot. (CE) Cumulative levels for the lipid mediator from the (C) docosahexaenoic acid, (D) eicosapentaenoic acid, and (E) arachidonic acid SPMs, arachidonic acid–derived LTB4, and ratio of SPM to LTB4. Results shown are mean ± SEM of n = 11 females and n = 13 males for BE. Statistical significance determined using Students 2-tailed unpaired t test; *P < 0.05 for CE.

References

    1. Writing Group Members. et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38–e360. doi: 10.1161/CIR.0000000000000350.
    1. Townsend N, Bhatnagar P, Wilkins E, Wickramasinghe K, Rayner M. In: Dicks E, ed. Cardiovascular Disease Statistics 2015. London, United Kingdom: British Heart Foundation; 2015. Accessed October 18, 2016.
    1. Barrett-Connor E. Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. Circulation. 1997;95(1):252–264. doi: 10.1161/01.CIR.95.1.252.
    1. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J. 1986;111(2):383–390. doi: 10.1016/0002-8703(86)90155-9.
    1. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science. 2005;308(5728):1583–1587. doi: 10.1126/science.1112062.
    1. Murphy E. Estrogen signaling and cardiovascular disease. Circ Res. 2011;109(6):687–696. doi: 10.1161/CIRCRESAHA.110.236687.
    1. Lowe GD. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Thromb Haemost. 2005;3(8):1618–1627. doi: 10.1111/j.1538-7836.2005.01416.x.
    1. Villar IC, et al. Suppression of endothelial P-selectin expression contributes to reduced cell trafficking in females: an effect independent of NO and prostacyclin. Arterioscler Thromb Vasc Biol. 2011;31(5):1075–1083. doi: 10.1161/ATVBAHA.111.223545.
    1. Yusuf S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–952. doi: 10.1016/S0140-6736(04)17018-9.
    1. Celermajer DS, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340(8828):1111–1115. doi: 10.1016/0140-6736(92)93147-F.
    1. Halcox JP, et al. Endothelial function predicts progression of carotid intima-media thickness. Circulation. 2009;119(7):1005–1012. doi: 10.1161/CIRCULATIONAHA.108.765701.
    1. Hingorani AD, et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation. 2000;102(9):994–999. doi: 10.1161/01.CIR.102.9.994.
    1. Bubb KJ, Khambata RS, Ahluwalia A. Sexual dimorphism in rodent models of hypertension and atherosclerosis. Br J Pharmacol. 2012;167(2):298–312. doi: 10.1111/j.1476-5381.2012.02036.x.
    1. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626–638. doi: 10.1038/nri.2016.90.
    1. Card JW, et al. Gender differences in murine airway responsiveness and lipopolysaccharide-induced inflammation. J Immunol. 2006;177(1):621–630. doi: 10.4049/jimmunol.177.1.621.
    1. Eckhoff DE, et al. Enhanced isolated pancreatic islet recovery and functionality in rats by 17beta-estradiol treatment of brain death donors. Surgery. 2004;136(2):336–345. doi: 10.1016/j.surg.2004.05.009.
    1. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature. 2000;407(6803):538–541. doi: 10.1038/35035131.
    1. Squadrito F, et al. 17Beta-oestradiol reduces cardiac leukocyte accumulation in myocardial ischaemia reperfusion injury in rat. Eur J Pharmacol. 1997;335(2-3):185–192. doi: 10.1016/S0014-2999(97)01201-6.
    1. Xing D, Miller A, Novak L, Rocha R, Chen YF, Oparil S. Estradiol and progestins differentially modulate leukocyte infiltration after vascular injury. Circulation. 2004;109(2):234–241. doi: 10.1161/01.CIR.0000105700.95607.49.
    1. Day RM, Harbord M, Forbes A, Segal AW. Cantharidin blisters: a technique for investigating leukocyte trafficking and cytokine production at sites of inflammation in humans. J Immunol Methods. 2001;257(1-2):213–220. doi: 10.1016/S0022-1759(01)00467-7.
    1. Xu H, Manivannan A, Crane I, Dawson R, Liversidge J. Critical but divergent roles for CD62L and CD44 in directing blood monocyte trafficking in vivo during inflammation. Blood. 2008;112(4):1166–1174. doi: 10.1182/blood-2007-06-098327.
    1. Pillay J, et al. A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1. J Clin Invest. 2012;122(1):327–336. doi: 10.1172/JCI57990.
    1. Dinh PH, Corraza F, Mestdagh K, Kassengera Z, Doyen V, Michel O. Validation of the cantharidin-induced skin blister as an in vivo model of inflammation. Br J Clin Pharmacol. 2011;72(6):912–920. doi: 10.1111/j.1365-2125.2011.04020.x.
    1. Brunner M, et al. Direct assessment of peripheral pharmacokinetics in humans: comparison between cantharides blister fluid sampling, in vivo microdialysis and saliva sampling. Br J Clin Pharmacol. 1998;46(5):425–431.
    1. Jenner W, et al. Characterisation of leukocytes in a human skin blister model of acute inflammation and resolution. PLoS ONE. 2014;9(3):e89375. doi: 10.1371/journal.pone.0089375.
    1. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510(7503):92–101. doi: 10.1038/nature13479.
    1. Serhan CN, Dalli J, Colas RA, Winkler JW, Chiang N. Protectins and maresins: new pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome. Biochim Biophys Acta. 2015;1851(4):397–413.
    1. Colas RA, Shinohara M, Dalli J, Chiang N, Serhan CN. Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. Am J Physiol, Cell Physiol. 2014;307(1):C39–C54.
    1. Beagley KW, Gockel CM. Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone. FEMS Immunol Med Microbiol. 2003;38(1):13–22. doi: 10.1016/S0928-8244(03)00202-5.
    1. Gubbels Bupp MR. Sex, the aging immune system, and chronic disease. Cell Immunol. 2015;294(2):102–110. doi: 10.1016/j.cellimm.2015.02.002.
    1. Ross R. Atherosclerosis — an inflammatory disease. N Engl J Med. 1999;340(2):115–126. doi: 10.1056/NEJM199901143400207.
    1. Chia S, Ludlam CA, Fox KA, Newby DE. Acute systemic inflammation enhances endothelium-dependent tissue plasminogen activator release in men. J Am Coll Cardiol. 2003;41(2):333–339. doi: 10.1016/S0735-1097(02)02701-8.
    1. Mullen MJ, et al. Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia. Circ Res. 2001;88(2):145–151. doi: 10.1161/01.RES.88.2.145.
    1. Mullen MJ, Thorne SA, Deanfield JE, Jones CJ. Non-invasive assessment of endothelial function. Heart. 1997;77(4):297–298. doi: 10.1136/hrt.77.4.297.
    1. Kleinbongard P, et al. Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. Free Radic Biol Med. 2003;35(7):790–796. doi: 10.1016/S0891-5849(03)00406-4.
    1. Lauer T, et al. Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action. Proc Natl Acad Sci U S A. 2001;98(22):12814–12819. doi: 10.1073/pnas.221381098.
    1. García-Cardeña G, et al. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature. 1998;392(6678):821–824. doi: 10.1038/33934.
    1. Russell KS, Haynes MP, Caulin-Glaser T, Rosneck J, Sessa WC, Bender JR. Estrogen stimulates heat shock protein 90 binding to endothelial nitric oxide synthase in human vascular endothelial cells. Effects on calcium sensitivity and NO release. J Biol Chem. 2000;275(7):5026–5030. doi: 10.1074/jbc.275.7.5026.
    1. Taguchi K, Matsumoto T, Kamata K, Kobayashi T. Akt/eNOS pathway activation in endothelium-dependent relaxation is preserved in aortas from female, but not from male, type 2 diabetic mice. Pharmacol Res. 2012;65(1):56–65. doi: 10.1016/j.phrs.2011.08.009.
    1. Kane MO, Anselm E, Rattmann YD, Auger C, Schini-Kerth VB. Role of gender and estrogen receptors in the rat aorta endothelium-dependent relaxation to red wine polyphenols. Vascul Pharmacol. 2009;51(2–3):140–146.
    1. Jones SP, Bolli R. The ubiquitous role of nitric oxide in cardioprotection. J Mol Cell Cardiol. 2006;40(1):16–23. doi: 10.1016/j.yjmcc.2005.09.011.
    1. Ha T, et al. Lipopolysaccharide-induced myocardial protection against ischaemia/reperfusion injury is mediated through a PI3K/Akt-dependent mechanism. Cardiovasc Res. 2008;78(3):546–553. doi: 10.1093/cvr/cvn037.
    1. Green DJ, Dawson EA, Groenewoud HM, Jones H, Thijssen DH. Is flow-mediated dilation nitric oxide mediated? A meta-analysis. Hypertension. 2014;63(2):376–382. doi: 10.1161/HYPERTENSIONAHA.113.02044.
    1. Parker BA, Tschakovsky ME, Augeri AL, Polk DM, Thompson PD, Kiernan FJ. Heterogenous vasodilator pathways underlie flow-mediated dilation in men and women. Am J Physiol Heart Circ Physiol. 2011;301(3):H1118–H1126. doi: 10.1152/ajpheart.00400.2011.
    1. Vitale C, Mendelsohn ME, Rosano GM. Gender differences in the cardiovascular effect of sex hormones. Nat Rev Cardiol. 2009;6(8):532–542. doi: 10.1038/nrcardio.2009.105.
    1. Bain BJ, England JM. Normal haematological values: sex difference in neutrophil count. Br Med J. 1975;1(5953):306–309. doi: 10.1136/bmj.1.5953.306.
    1. Bain BJ, England JM. Variations in leucocyte count during menstrual cycle. Br Med J. 1975;2(5969):473–475. doi: 10.1136/bmj.2.5969.473.
    1. Josefsson E, Tarkowski A, Carlsten H. Anti-inflammatory properties of estrogen. I. In vivo suppression of leukocyte production in bone marrow and redistribution of peripheral blood neutrophils. Cell Immunol. 1992;142(1):67–78. doi: 10.1016/0008-8749(92)90269-U.
    1. Hafezi-Moghadam A, Thomas KL, Prorock AJ, Huo Y, Ley K. L-selectin shedding regulates leukocyte recruitment. J Exp Med. 2001;193(7):863–872. doi: 10.1084/jem.193.7.863.
    1. Gomez-Sanchez L, et al. Leukocyte subtype counts and its association with vascular structure and function in adults with intermediate cardiovascular risk. MARK study. PLoS One. 2015;10(4):e0119963. doi: 10.1371/journal.pone.0119963.
    1. Honkanen RE. Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. FEBS Lett. 1993;330(3):283–286. doi: 10.1016/0014-5793(93)80889-3.
    1. Bertaux B, Prost C, Heslan M, Dubertret L. Cantharide acantholysis: endogenous protease activation leading to desmosomal plaque dissolution. Br J Dermatol. 1988;118(2):157–165. doi: 10.1111/j.1365-2133.1988.tb01769.x.
    1. Suffredini AF, Fantuzzi G, Badolato R, Oppenheim JJ, O’Grady NP. New insights into the biology of the acute phase response. J Clin Immunol. 1999;19(4):203–214. doi: 10.1023/A:1020563913045.
    1. Viola A, Luster AD. Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol. 2008;48:171–197. doi: 10.1146/annurev.pharmtox.48.121806.154841.
    1. Colby JK, et al. Resolvin D3 and aspirin-triggered resolvin D3 are protective for injured epithelia. Am J Pathol. 2016;186(7):1801–1813. doi: 10.1016/j.ajpath.2016.03.011.
    1. Chinetti-Gbaguidi G, Colin S, Staels B. Macrophage subsets in atherosclerosis. Nat Rev Cardiol. 2015;12(1):10–17.
    1. Fredman G, et al. Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B(4) synthesis by inhibiting a calcium-activated kinase pathway. Proc Natl Acad Sci U S A. 2014;111(40):14530–14535. doi: 10.1073/pnas.1410851111.
    1. Dona M, et al. Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood. 2008;112(3):848–855. doi: 10.1182/blood-2007-11-122598.
    1. Dalli J, Serhan CN. Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood. 2012;120(15):e60–e72. doi: 10.1182/blood-2012-04-423525.
    1. Kasuga K, et al. Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution. J Immunol. 2008;181(12):8677–8687. doi: 10.4049/jimmunol.181.12.8677.
    1. Pergola C, et al. ERK-mediated regulation of leukotriene biosynthesis by androgens: a molecular basis for gender differences in inflammation and asthma. Proc Natl Acad Sci U S A. 2008;105(50):19881–19886. doi: 10.1073/pnas.0809120105.
    1. Buckley CD, Gilroy DW, Serhan CN. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity. 2014;40(3):315–327. doi: 10.1016/j.immuni.2014.02.009.
    1. Donald AE, et al. Non-invasive assessment of endothelial function: which technique? J Am Coll Cardiol. 2006;48(9):1846–1850. doi: 10.1016/j.jacc.2006.07.039.
    1. Ignarro LJ, Fukuto JM, Griscavage JM, Rogers NE, Byrns RE. Oxidation of nitric oxide in aqueous solution to nitrite but not nitrate: comparison with enzymatically formed nitric oxide from L-arginine. Proc Natl Acad Sci U S A. 1993;90(17):8103–8107. doi: 10.1073/pnas.90.17.8103.
    1. Kapil V, Khambata RS, Robertson A, Caulfield MJ, Ahluwalia A. Dietary nitrate provides sustained blood pressure lowering in hypertensive patients: a randomized, phase 2, double-blind, placebo-controlled study. Hypertension. 2015;65(2):320–327. doi: 10.1161/HYPERTENSIONAHA.114.04675.
    1. Williams B, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ. 2004;328(7440):634–640. doi: 10.1136/bmj.328.7440.634.
    1. Hickson SS, Butlin M, Broad J, Avolio AP, Wilkinson IB, McEniery CM. Validity and repeatability of the Vicorder apparatus: a comparison with the SphygmoCor device. Hypertens Res. 2009;32(12):1079–1085. doi: 10.1038/hr.2009.154.
    1. Sidhu JS, Cowan D, Tooze JA, Kaski JC. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease. Am Heart J. 2004;147(6):e25.
    1. Velmurugan S, et al. Antiplatelet effects of dietary nitrate in healthy volunteers: involvement of cGMP and influence of sex. Free Radic Biol Med. 2013;65:1521–1532. doi: 10.1016/j.freeradbiomed.2013.06.031.
    1. Evans BJ, Haskard DO, Finch JR, Hambleton IR, Landis RC, Taylor KM. The inflammatory effect of cardiopulmonary bypass on leukocyte extravasation in vivo. J Thorac Cardiovasc Surg. 2008;135(5):999–1006. doi: 10.1016/j.jtcvs.2007.08.071.
    1. Janes KA, Yaffe MB. Data-driven modelling of signal-transduction networks. Nat Rev Mol Cell Biol. 2006;7(11):820–828. doi: 10.1038/nrm2041.

Source: PubMed

3
Abonnere